AASLD: Six Months of Novel Agent Works in Hep C (CME/CE)
BOSTON (MedPage Today) — A shorter, six-month course of the investigational protease inhibitor boceprevir added to standard combination treatment appears just as effective as almost a full year of therapy for patients with a challenging subtype of hepatitis C, researchers reported here.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com